NCT03255083View on ClinicalTrials.gov

DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 10, 2019

Primary Completion Date

September 4, 2020

Study Completion Date

September 4, 2020

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

DS-1205c

DS-1205c 200 mg capsule

DRUG

Osimertinib

Osimertinib 80 mg tablet

Trial Locations (7)

10048

National Taiwan University Hospital, Taipei

11031

Taipei Medical University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

23561

Taipei Medical University, Shuang Ho Hospital, New Taipei City

40447

China Medical University Hospital, Taichung

40705

Taichung Veterans General Hospital, Taichung

70457

National Cheng-Kung University Hospital, Tainan City

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY